James Gordon CFA
Stock Analyst at Barclays
(3.49)
# 2,255
Out of 4,476 analysts
129
Total ratings
69.4%
Success rate
7.3%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 530.00 | $479.00 | +10.65% | 1 | Jul 3, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 2,500 | $1,861.29 | +34.32% | 7 | Jul 2, 2026 | |
| SWX: SDZ Sandoz Group AG | Maintained: Buy | CHF 75.00 → CHF 81.00 | $72.34 | +11.97% | 7 | Jul 1, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 200.00 | $179.55 | +11.39% | 22 | Jul 1, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | $14,456.00 | +14.14% | 13 | Jun 30, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 120.00 | $127.92 | -6.19% | 8 | Jun 30, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | 1,800p → 1,900p | $2,015.00 | -5.71% | 19 | Jun 29, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €900.00 | $817.40 | +10.11% | 13 | Jun 25, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Maintained: Sell | 1,350p | $1,548.00 | -12.79% | 3 | Jun 23, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | CHF 410.00 | $340.60 | +20.38% | 13 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | kr 300.00 | $326.48 | -8.11% | 16 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €85.00 | $75.81 | +12.12% | 6 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €22.00 | $26.90 | n/a | 1 | Jan 23, 2025 |
Swedish Orphan Biovitrum AB (publ)
Jul 3, 2026
Maintained: Buy
Price Target: kr 530.00
Current: $479.00
Upside: +10.65%
Genmab A/S
Jul 2, 2026
Maintained: Buy
Price Target: kr 2,500
Current: $1,861.29
Upside: +34.32%
Sandoz Group AG
Jul 1, 2026
Maintained: Buy
Price Target: CHF 75.00 → CHF 81.00
Current: $72.34
Upside: +11.97%
Galderma Group AG
Jul 1, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: $179.55
Upside: +11.39%
AstraZeneca PLC
Jun 30, 2026
Maintained: Buy
Price Target: 16,500p
Current: $14,456.00
Upside: +14.14%
Novartis AG
Jun 30, 2026
Maintained: Hold
Price Target: CHF 120.00
Current: $127.92
Upside: -6.19%
GSK plc
Jun 29, 2026
Maintained: Sell
Price Target: 1,800p → 1,900p
Current: $2,015.00
Upside: -5.71%
argenx SE
Jun 25, 2026
Maintained: Buy
Price Target: €900.00
Current: $817.40
Upside: +10.11%
Hikma Pharmaceuticals PLC
Jun 23, 2026
Maintained: Sell
Price Target: 1,350p
Current: $1,548.00
Upside: -12.79%
Roche Holding AG
May 26, 2026
Maintained: Buy
Price Target: CHF 410.00
Current: $340.60
Upside: +20.38%
May 19, 2026
Maintained: Hold
Price Target: kr 300.00
Current: $326.48
Upside: -8.11%
Apr 23, 2026
Maintained: Hold
Price Target: €85.00
Current: $75.81
Upside: +12.12%
Jan 23, 2025
Downgraded: Sell
Price Target: €22.00
Current: $26.90
Upside: n/a